KBC Securities - DEME : A break-up on good terms

Report

KBC Securities

Olivier Vandewoude

DEME : A break-up on good terms

Yesterday, DEME debuted spectacularly on Euronext Brussels, with a rally of 10% in a down market. The pure-play marine solutions provider was spun-off from the CFE Group, which investors seem to appreciate. DEME is mainly active in dredging and the booming offshore wind market. They have the track-record, the fleet and the market share to maintain their favourable position. The hydrogen portfolio and deep-sea mining activities are a nice plus. We set our target price at €123 and rate the stock BUY

01/07/2022 1 EN

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Olivier Vandewoude

Other Reports from KBC Securities

Guy Sips ... (+6)

Guy Sips
Mathijs Geerts Danau
Michiel Declercq
Thibault Leneeuw
Thomas Couvreur
Wim Hoste

Morning Notes : ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

: ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

6h / 45m 6h / 45m 1 EN

Wim Hoste

Wim Hoste

Heineken FIRST LOOK: FY25 operating profit +4.4%, FY26 guidance of 2-6% growth

Heineken's FY25 top line and operating profit figures were slightly better than our forecasts with operating profit in absolute terms in line with consensus. Heineken guides again for sizeable savings efforts in FY26 with operating profit growth guidance calling for a 2-6% range (vs our and consensus forecasts of c. 5%). We still appreciate Heineken for the sizeable self-help initiatives which should support organic earnings growth in the coming years, but acknowledge that the bumpier volume evolution of the past few years makes the investment case a bit less predictable and hence also less ap...

7h / 12m 7h / 12m 1 EN

Mathijs Geerts Danau

Mathijs Geerts Danau

Pharvaris To present clinical data at the AAAAI 2026

Pharvaris will present multiple datasets at AAAAI 2026, including topline RAPIDe-3 results, final CHAPTER-1 data, supporting evidence for the extended-release formulation, AMRA endpoint validation, and results from a new kinin biomarker assay. We look forward to the prophylactic phase 3 (CHAPTER-3) readout in 3Q26 and reiterate our Buy and $ 36 TP.

7h / 32m 7h / 32m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

DEME : A break-up on good terms

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

Heineken FIRST LOOK: FY25 operating profit +4.4%, FY26 guidance of 2-6% growth

Pharvaris To present clinical data at the AAAAI 2026

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe